Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
CBM's Cash to Debt is ranked higher than
99% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. CBM: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CBM' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.25 Max: No Debt
Current: No Debt
Equity to Asset 0.62
CBM's Equity to Asset is ranked lower than
59% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. CBM: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
CBM' s Equity to Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.44 Max: 0.74
Current: 0.62
0.22
0.74
Interest Coverage 1812.51
CBM's Interest Coverage is ranked lower than
54% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 1812.51 )
Ranked among companies with meaningful Interest Coverage only.
CBM' s Interest Coverage Range Over the Past 10 Years
Min: 2.23  Med: 14.64 Max: 9999.99
Current: 1812.51
2.23
9999.99
F-Score: 7
Z-Score: 6.88
M-Score: -3.03
WACC vs ROIC
19.21%
24.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 22.13
CBM's Operating margin (%) is ranked higher than
87% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. CBM: 22.13 )
Ranked among companies with meaningful Operating margin (%) only.
CBM' s Operating margin (%) Range Over the Past 10 Years
Min: -2.77  Med: 10.34 Max: 21
Current: 22.13
-2.77
21
Net-margin (%) 14.16
CBM's Net-margin (%) is ranked higher than
83% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. CBM: 14.16 )
Ranked among companies with meaningful Net-margin (%) only.
CBM' s Net-margin (%) Range Over the Past 10 Years
Min: -6.61  Med: 6.29 Max: 82.87
Current: 14.16
-6.61
82.87
ROE (%) 22.02
CBM's ROE (%) is ranked higher than
94% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. CBM: 22.02 )
Ranked among companies with meaningful ROE (%) only.
CBM' s ROE (%) Range Over the Past 10 Years
Min: -12.29  Med: 12.78 Max: 120.02
Current: 22.02
-12.29
120.02
ROA (%) 12.49
CBM's ROA (%) is ranked higher than
92% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. CBM: 12.49 )
Ranked among companies with meaningful ROA (%) only.
CBM' s ROA (%) Range Over the Past 10 Years
Min: -4.94  Med: 4.65 Max: 42.71
Current: 12.49
-4.94
42.71
ROC (Joel Greenblatt) (%) 37.91
CBM's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. CBM: 37.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CBM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1.19  Med: 12.95 Max: 33.38
Current: 37.91
-1.19
33.38
Revenue Growth (3Y)(%) 13.40
CBM's Revenue Growth (3Y)(%) is ranked higher than
68% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CBM: 13.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CBM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.1  Med: 1.50 Max: 13.4
Current: 13.4
-22.1
13.4
EBITDA Growth (3Y)(%) 13.80
CBM's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. CBM: 13.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CBM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -27.5  Med: 4.50 Max: 33.1
Current: 13.8
-27.5
33.1
EPS Growth (3Y)(%) -5.60
CBM's EPS Growth (3Y)(%) is ranked lower than
51% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. CBM: -5.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CBM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -82.6  Med: 7.90 Max: 79.7
Current: -5.6
-82.6
79.7
» CBM's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CBM Guru Trades in Q2 2015

Joel Greenblatt 268,701 sh (+341.54%)
Jim Simons 355,100 sh (-12.94%)
Chuck Royce 424,500 sh (-25.41%)
Paul Tudor Jones 22,492 sh (-48.22%)
» More
Q3 2015

CBM Guru Trades in Q3 2015

Jim Simons 348,100 sh (-1.97%)
Paul Tudor Jones 20,971 sh (-6.76%)
Chuck Royce 337,500 sh (-20.49%)
Joel Greenblatt 137,090 sh (-48.98%)
» More
Q4 2015

CBM Guru Trades in Q4 2015

Jim Simons 319,200 sh (-8.30%)
Joel Greenblatt 110,565 sh (-19.35%)
Chuck Royce 201,500 sh (-40.30%)
Paul Tudor Jones 6,000 sh (-71.39%)
» More
Q1 2016

CBM Guru Trades in Q1 2016

Third Avenue Management 76,681 sh (New)
Columbia Wanger 287,570 sh (New)
Paul Tudor Jones 7,400 sh (+23.33%)
Chuck Royce 203,298 sh (+0.89%)
Joel Greenblatt Sold Out
Jim Simons 162,300 sh (-49.15%)
» More
» Details

Insider Trades

Latest Guru Trades with CBM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:SHSE:600645, SHSE:600161, SHSE:603566, BOM:532523, NAS:NKTR, SZSE:300347 » details
Traded in other countries:XBX.Germany,
Cambrex Corp is a life sciences company. It provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics.

Cambrex Corp was incorporated as a Delaware corporation in 1981 and began business in December 1981. It is a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. The Company primarily supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment. The Company participates in markets that serve the healthcare industry. Customers include generic drug companies and companies that discover and commercialize new small molecule human therapeutics using organic chemistry. The Company uses its technical expertise in a wide range of chemical processes to meet the needs of its customers for high quality products and services for specialized applications. The Company's business is primarily comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Products and services are supplied globally to innovator and generic drug companies. Products include APIs, pharmaceutical intermediates and, to a lesser extent, other fine chemicals. The Company's products and services are sold to a diverse group of several hundred customers, with one customer, Gilead Sciences, Inc. The manufacturing of pharmaceutical products is subject to extensive regulation by governmental authorities, including the FDA, the European Medicines Agency and comparable regulatory authorities in other countries.

Guru Investment Theses on Cambrex Corp

Third Avenue Comments on Cambrex Corp - May 27, 2016

Cambrex Corp. (NYSE:CBM) We took advantage of the February sell off in the market to acquire shares of Cambrex at around $38 per share, an attractive discount to our estimate of NAV. We see the combination of a strong balance sheet and a healthy revenue outlook as supportive for book value growth to continue, given the dynamics of Cambrex's business.


Cambrex is a well-financed specialty chemical company focused on life sciences; it develops and commercializes active pharmaceutical ingredients (APIs). Cambrex also produces Generic APIs, Controlled Substance APIs and is expanding into finished-dosage generic API manufacturing. Cambrex's API business is unique in that it manufactures the active ingredient in several leading pharmaceuticals and serves as a supplier to various drug companies. As such, it generates revenues from volumes sold and not price per finished pill. Cambrex's customers focus not only on product purity but also on quality, consistency and documentation of the manufacturing process ascompetitive attributes.


Several long-term drivers support revenue growth for Cambrex.



  1. Cambrex is a substantial beneficiary of the U.S. Federal Drug Administration's (FDA) significantly enhanced effort to ensure quality manufacturing processes. The company has benefitted as larger pharmaceutical companies have re-shored their API sourcing activities to "Western" Current Good Manufacturing Practice (CGMP) companies.

  2. Industry growth remains healthy, aided by the increasing number of small molecule drug developments and pending regulatory approvals in the U.S. and Europe.

  3. Pharmaceutical companies are continuing to reduce their own manufacturing activities and thus turning to outsourcing firms, such as Cambrex, to focus on new drug development.

Cambrex is in the midst of a capacity expansion in Charles City, Iowa that should drive significant revenue growth as this capacity is completed and filled for the next few years.



From Chip Rewey's second quarter 2016 Third Avenue Small-Cap Value Fund letter.



Check out Martin Whitman,Third Avenue Management latest stock trades

Top Ranked Articles about Cambrex Corp

Third Avenue Comments on Cambrex Corp Guru stock highlight
Cambrex Corp. (NYSE:CBM) We took advantage of the February sell off in the market to acquire shares of Cambrex at around $38 per share, an attractive discount to our estimate of NAV. We see the combination of a strong balance sheet and a healthy revenue outlook as supportive for book value growth to continue, given the dynamics of Cambrex's business.

Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.98
CBM's P/E(ttm) is ranked higher than
58% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.15 vs. CBM: 24.98 )
Ranked among companies with meaningful P/E(ttm) only.
CBM' s P/E(ttm) Range Over the Past 10 Years
Min: 1.05  Med: 16.17 Max: 63.2
Current: 24.98
1.05
63.2
Forward P/E 16.78
CBM's Forward P/E is ranked higher than
54% of the 94 Companies
in the Global Biotechnology industry.

( Industry Median: 17.15 vs. CBM: 16.78 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.12
CBM's PE(NRI) is ranked higher than
59% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 30.43 vs. CBM: 25.12 )
Ranked among companies with meaningful PE(NRI) only.
CBM' s PE(NRI) Range Over the Past 10 Years
Min: 5.17  Med: 16.14 Max: 94.8
Current: 25.12
5.17
94.8
Price/Owner Earnings (ttm) 15.27
CBM's Price/Owner Earnings (ttm) is ranked higher than
75% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 37.01 vs. CBM: 15.27 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CBM' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 1.28  Med: 17.70 Max: 119
Current: 15.27
1.28
119
P/B 4.66
CBM's P/B is ranked lower than
64% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. CBM: 4.66 )
Ranked among companies with meaningful P/B only.
CBM' s P/B Range Over the Past 10 Years
Min: 0.61  Med: 2.15 Max: 5.9
Current: 4.66
0.61
5.9
P/S 3.58
CBM's P/S is ranked higher than
80% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. CBM: 3.58 )
Ranked among companies with meaningful P/S only.
CBM' s P/S Range Over the Past 10 Years
Min: 0.18  Med: 1.28 Max: 10.86
Current: 3.58
0.18
10.86
PFCF 23.37
CBM's PFCF is ranked higher than
59% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 26.95 vs. CBM: 23.37 )
Ranked among companies with meaningful PFCF only.
CBM' s PFCF Range Over the Past 10 Years
Min: 4.86  Med: 15.35 Max: 276
Current: 23.37
4.86
276
POCF 11.53
CBM's POCF is ranked higher than
77% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. CBM: 11.53 )
Ranked among companies with meaningful POCF only.
CBM' s POCF Range Over the Past 10 Years
Min: 2.91  Med: 10.86 Max: 63.52
Current: 11.53
2.91
63.52
EV-to-EBIT 14.79
CBM's EV-to-EBIT is ranked higher than
64% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. CBM: 14.79 )
Ranked among companies with meaningful EV-to-EBIT only.
CBM' s EV-to-EBIT Range Over the Past 10 Years
Min: -118.8  Med: 11.60 Max: 306.6
Current: 14.79
-118.8
306.6
EV-to-EBITDA 12.61
CBM's EV-to-EBITDA is ranked higher than
64% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. CBM: 12.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.8  Med: 8.00 Max: 35.9
Current: 12.61
-0.8
35.9
PEG 1.68
CBM's PEG is ranked higher than
65% of the 93 Companies
in the Global Biotechnology industry.

( Industry Median: 2.28 vs. CBM: 1.68 )
Ranked among companies with meaningful PEG only.
CBM' s PEG Range Over the Past 10 Years
Min: 0.48  Med: 1.29 Max: 7.94
Current: 1.68
0.48
7.94
Shiller P/E 68.44
CBM's Shiller P/E is ranked lower than
57% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 51.13 vs. CBM: 68.44 )
Ranked among companies with meaningful Shiller P/E only.
CBM' s Shiller P/E Range Over the Past 10 Years
Min: 47.88  Med: 129.44 Max: 2516
Current: 68.44
47.88
2516
Current Ratio 2.72
CBM's Current Ratio is ranked lower than
67% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. CBM: 2.72 )
Ranked among companies with meaningful Current Ratio only.
CBM' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.55 Max: 5.19
Current: 2.72
0.9
5.19
Quick Ratio 1.46
CBM's Quick Ratio is ranked lower than
79% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. CBM: 1.46 )
Ranked among companies with meaningful Quick Ratio only.
CBM' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.42 Max: 4.55
Current: 1.46
0.5
4.55
Days Inventory 168.04
CBM's Days Inventory is ranked lower than
64% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 127.50 vs. CBM: 168.04 )
Ranked among companies with meaningful Days Inventory only.
CBM' s Days Inventory Range Over the Past 10 Years
Min: 86.7  Med: 130.66 Max: 139.21
Current: 168.04
86.7
139.21
Days Sales Outstanding 38.33
CBM's Days Sales Outstanding is ranked higher than
71% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. CBM: 38.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.89  Med: 59.82 Max: 81.77
Current: 38.33
30.89
81.77
Days Payable 54.45
CBM's Days Payable is ranked lower than
53% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 58.35 vs. CBM: 54.45 )
Ranked among companies with meaningful Days Payable only.
CBM' s Days Payable Range Over the Past 10 Years
Min: 36.73  Med: 46.83 Max: 63.55
Current: 54.45
36.73
63.55

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 20.89
CBM's Price/Net Current Asset Value is ranked lower than
87% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. CBM: 20.89 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CBM' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.47  Med: 23.20 Max: 107.17
Current: 20.89
2.47
107.17
Price/Tangible Book 5.29
CBM's Price/Tangible Book is ranked lower than
62% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. CBM: 5.29 )
Ranked among companies with meaningful Price/Tangible Book only.
CBM' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.62  Med: 3.85 Max: 14.12
Current: 5.29
1.62
14.12
Price/Projected FCF 2.27
CBM's Price/Projected FCF is ranked higher than
68% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. CBM: 2.27 )
Ranked among companies with meaningful Price/Projected FCF only.
CBM' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.83  Med: 2.21 Max: 12.66
Current: 2.27
0.83
12.66
Price/Median PS Value 2.75
CBM's Price/Median PS Value is ranked lower than
87% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. CBM: 2.75 )
Ranked among companies with meaningful Price/Median PS Value only.
CBM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 1.17 Max: 7.4
Current: 2.75
0.21
7.4
Price/Peter Lynch Fair Value 1.46
CBM's Price/Peter Lynch Fair Value is ranked higher than
58% of the 60 Companies
in the Global Biotechnology industry.

( Industry Median: 1.68 vs. CBM: 1.46 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CBM' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.58  Med: 1.21 Max: 8.25
Current: 1.46
0.58
8.25
Price/Graham Number 2.43
CBM's Price/Graham Number is ranked higher than
62% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. CBM: 2.43 )
Ranked among companies with meaningful Price/Graham Number only.
CBM' s Price/Graham Number Range Over the Past 10 Years
Min: 0.78  Med: 1.82 Max: 12.14
Current: 2.43
0.78
12.14
Earnings Yield (Greenblatt) (%) 6.80
CBM's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. CBM: 6.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CBM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 8.20 Max: 209.9
Current: 6.8
0.3
209.9
Forward Rate of Return (Yacktman) (%) 19.23
CBM's Forward Rate of Return (Yacktman) (%) is ranked higher than
59% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 14.18 vs. CBM: 19.23 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CBM' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -35.2  Med: -4.80 Max: 20.7
Current: 19.23
-35.2
20.7

More Statistics

Revenue (TTM) (Mil) $450.5
EPS (TTM) $ 1.95
Beta2.39
Short Percentage of Float5.95%
52-Week Range $29.50 - 55.60
Shares Outstanding (Mil)31.98

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 482 523
EPS ($) 2.52 2.90
EPS without NRI ($) 2.52 2.90
EPS Growth Rate
(3Y to 5Y Estimate)
8.00%
» More Articles for CBM

Headlines

Articles On GuruFocus.com
Third Avenue Comments on Cambrex Corp May 27 2016 
Chip Rewey's Third Avenue Small-Cap Value Fund 2nd Quarter Commentary May 27 2016 
Royce Smaller-Companies Growth Fund Annual Letter Mar 19 2016 
Royce Smaller-Companies Growth Fund Shareholder Letter Sep 20 2015 
Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
Cambrex Announces Closing of New $500 Million Senior Credit Facility May 23 2016
CAMBREX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... May 23 2016
Cambrex Announces Closing of New $500 Million Senior Credit Facility May 23 2016
Cambrex to Present at UBS Global Healthcare Conference May 16 2016
Cambrex to Present at UBS Global Healthcare Conference May 16 2016
Breakout Watch: Big Cap Medical Stock Zimmer Biomet Nears Buy Zone May 10 2016
New Strong Buy Stocks for May 10th May 10 2016
ETF’s with exposure to Cambrex Corp. : May 9, 2016 May 09 2016
CAMBREX CORP Financials May 05 2016
Cambrex Corp. :CBM-US: Earnings Analysis: Q1, 2016 By the Numbers May 04 2016
Cambrex (CBM) Catches Eye: Stock Adds 8.5% in Session May 02 2016
Cambrex posts 1Q profit Apr 29 2016
Cambrex posts 1Q profit Apr 29 2016
Gilead Stock: Analyzing 5 Key Suppliers (GILD) Apr 29 2016
Edited Transcript of CBM earnings conference call or presentation 29-Apr-16 12:30pm GMT Apr 29 2016
Cambrex Corp Earnings Call scheduled for 8:30 am ET today Apr 29 2016
CAMBREX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Apr 29 2016
Cambrex Reports First Quarter 2016 Financial Results Apr 29 2016
CAMBREX CORP Files SEC form 10-Q, Quarterly Report Apr 29 2016
Q1 2016 Cambrex Corp Earnings Release - Before Market Open Apr 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)